The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs May 23.) ArQule, Inc. (NASDAQ: ARQL ) Turning Point ...

Some stocks are best avoided. We don't wish catastrophic capital loss on anyone. Anyone who held Organovo Holdings, Inc. (NASDAQ:ONVO) for five years would be nursing their metaphorical wounds since the share price dropped 83...

Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that Chief Medical Officer, Dr. Steven G. Hughes, is scheduled to speak at the inaugural Cell & Gene Meeting on the Mediterranean to be held April 23-25 in Barcelona, Spain. Organovo is changing the shape of life science research and transforming medical care.

Organovo Holdings, Inc. (ONVO) (“Organovo”) today announced that it will participate in a panel at the 31st Annual ROTH Conference, being held in Laguna Niguel, Ca. from March 17-19, 2019. The Company will also participate in one-on-one meetings with investors who are registered to attend the conference.

Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member. Ms. Carolyn Beaver, former Chief Financial Officer of Sequenom Inc., will join Organovo’s board, effective immediately. Ms. Beaver’s appointment increases the number of Organovo directors to nine.

On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

A look at the shareholders of Organovo Holdings, Inc. (NASDAQ:ONVO) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual
Read More...

Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that it has entered into a cell and tissue clinical sourcing agreement with the International Institute for the Advancement of Medicine (“IIAM”). Under the terms of the agreement, IIAM will provide Organovo with donated organs that have not been utilized for transplantation with high potential benefit for generating the cell-based building blocks for Organovo’s therapeutic liver tissue development program.

On a per-share basis, the San Diego-based company said it had a loss of 5 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...